ABCG2 and cancer: ABCG2 often lowers the bioavailability of other drugs such as rosuvastatin (Keskitalo et al., 2009; Tomlinson et al., 2010), which is widely used to treat dyslipidemia, and sunitinib (Mizuno et al., 2010), a multi-targeted receptor tyrosine kinase inhibitor used in cancer chemotherapy.